Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti‐TNF treatmentVince Biemans, Jeroen M. Jansen, Alexander Bodelier et al.|Alimentary Pharmacology & Therapeutics|2020Cited by 129
Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registryVince Biemans, Jasmijn A M Sleutjes, Annemarie C. de Vries et al.|Alimentary Pharmacology & Therapeutics|2020Cited by 87
Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of lifeShannon L. Kanis, C. Janneke van der Woude, Sanne Modderman et al.|Gut|2020Cited by 81
Increased Discontinuation Rates of Anti-TNF Therapy in Elderly Inflammatory Bowel Disease PatientsMichiel E. de Jong, Frank Hoentjen, Lisa Smits et al.|Journal of Crohn s and Colitis|2020Cited by 75
Clinical Outcomes of Covid-19 in Patients With Inflammatory Bowel Disease: A Nationwide Cohort StudyLauranne Derikx, Frank Hoentjen, Marten A. Lantinga et al.|Journal of Crohn s and Colitis|2020Cited by 71